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Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. With an ageing population, it
is anticipated that the number of AMD cases will increase dramatically, making a solution to this debilitating disease an urgent
requirement for the socioeconomic future of the European Union and worldwide. The present paper reviews the limitations of
the current therapies as well as the socioeconomic impact of the AMD. There is currently no cure available for AMD, and even
palliative treatments are rare. Treatment options show several side effects, are of high cost, and only treat the consequence, not the
cause of the pathology. For that reason, many options involving cell therapy mainly based on retinal and iris pigment epithelium
cells as well as stem cells are being tested. Moreover, tissue engineering strategies to design and manufacture scaffolds to mimic
Bruch’s membrane are very diverse and under investigation. Both alternative therapies are aimed to prevent and/or cure AMD and
are reviewed herein.
1. Age-Related Macular Degeneration:
Socioeconomic Burden and Limitations
of Current Therapies
1.1. General Introduction. Age-related macular degeneration
(AMD) is one of the leading causes of vision loss and the
most common cause (almost epidemic) of blindness in indu-
strialized countries. It is the first source of legal blindness
(visual acuity < 20/200) in Europe and mainly affects peo-
ple over the age of 50 affecting about 30 million people
worldwide. The dramatic loss of autonomy and life quality
associatedwithAMD [1, 2] leads to increased costs for health-
care and long-term care. AMD is multifactorial but clearly
age-related pathology. The number of affected people is exp-
ected to double by the year 2020 as a result of ageing of the
world’s population. Even, in developed countries, AMD is
gaining attention due to increased life expectancy and imp-
roved visual care facilities [3].
AMD is an inflammatory chronic progressive eye disease
with damage to retinal pigment epithelium (RPE) cells in
its early stage, while late stage has two distinct forms: the
slowly progressing “nonvascular” and the rapidly progressing
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“neovascular” AMD [4]. However, both forms eventually lead
to blindness [5] through degeneration of retinal pigment
epithelium (RPE) and posterior photoreceptor (PR) cells.
Moreover, with age, the metabolic activities of RPE cells
decrease leading to deposition of debris on and in BM
and decreased turnover and degradation of the extracellular
matrix (ECM) resulting in altered filtration of nutrients and
metabolic wastes which affects attachment of RPE cells to the
BM. The resulting altered metabolism and death of the RPE
cells cause the hypopigmentation observed in early AMD [6].
Probably, the presence of debris triggers a local inflammatory
response that activates the immune system, causing a chronic
and excessive immune response with further damage to the
retina [7]. Moreover, patient and in vitro studies reveal that
cells do not attach to old or damaged BM and do not form
a monolayer over the area of degenerated RPE cells [8]. In
AMD patients, BM no longer supports the normal functions
of RPE cells, and the RPE cells are no longer able to maintain
a normal BM [8, 9].
1.2. Limitations of Current Therapies in Clinical Use. Tradi-
tional therapeutic products targeting degenerative diseases
have largely focused on palliative forms of treatment that
mainly ameliorate or control the symptoms of a disease
without addressing the underlying biological cause. There
is currently no cure available for AMD, and even palliative
treatments are rare. Treatment options span a broad range of
therapeutic approaches, including thermal laser photocoag-
ulation, surgical approaches (excision, displacement, or tran-
splantation), and new treatments targeting the choroidal
neovascularization (CNV) component and its pathogenic
cascade, such as verteporfin with photodynamic therapy
(vPDT) and more recently antivascular endothelial growth
factor (VEGF) therapies [10].
1.2.1. Intermediate and Advanced AMD Prevention. In addi-
tion to the intake of vitamin and minerals supplements
described by the two AREDS studies, stopping smoking and
a healthy diet are strongly recommended.
1.2.2. Wet/Vascular AMD Treatments
Laser Photocoagulation and Photodynamic Therapy. Treat-
ment strategies for the neovascular form of AMD had been
focused several years ago on the prevention of further
progress of the CNV either with laser photocoagulation
for extrafoveal CNV [11–13] or with photodynamic therapy
(PDT) [14]. Although PDT has become increasingly preva-
lent, its effect on the patients’ vision is limited; there is a large
number of CNV recurrences reported after PDT and the
unpredictable repetition of treatments in 3-month inter-
vals in PDT treatment [14–16]. Thermal laser successfully
prevented the proliferation of CNV; however, visual loss
and recurrences impaired the treatment benefit. Using non-
thermal laser energy through vPDT appeared as a healthy
alternative, but again, it was unsatisfying given the inability
to improve vision in a majority of patients [10].
Anti-VEGF Therapy. Vascular endothelial growth factor
(VEGF-A) is the most potent promoter of angiogenesis and
its role in the pathogenesis of neovascular AMD is well
recognized [17, 18]. The advent of intravitreous VEGF inhi-
bitors has revolutionized the management of neovascular
AMD. A portion of patients with neovascular AMD can be
symptomatically treated with VEGF inhibitors that are effec-
tive in preventing the progression of vascular AMD with
some vision recovery in only 30% of patients. Monthly
injections of Ranibizumab or Bevacizumab (off label) are the
current, gold standard therapy in the management of neo-
vascular AMD. Individualized treatment regimens, including
traditional PRN (pro-re-nata) and “treat and extend,” may
yield visual outcomes comparable with monthly dosing,
although close followup and frequent treatments are still
needed. However, inhibition of vascularization only main-
tains temporarily the status quo in the majority of patients
indicating that neovascularization is a late event in the devel-
opment of AMD and certainly not the causative event. In
addition, as VEGF is an essential factor for cell survival, it has
been demonstrated that the sustained blocking of VEGF can
lead to undesirable adverse effects, such as chorioretinal
atrophy [19, 20]. Recent preclinical studies inmonkeys clearly
show that anti-VEGF therapy has a strong reducing effect on
the diameter of the choriocapillaris [21]. These findings
offer an explanation why RPE cells and retinal atrophy may
develop.
In minimally classic/occult trial of the anti-VEGF anti-
body ranibizumab in the treatment of neovascular age-
related macular degeneration (MARINA) study, patients
receiving the 0.5mg dose of ranibizumab experienced a 21.4
letter improvement compared with sham injections, and in
ANCHOR, they demonstrated a 20.5 letter improvement
compared with those receiving photodynamic therapy [22].
Data from the CATT study showed that patients who were
scrutinized monthly experienced similar outcomes at years
1 and 2 whether treated monthly or PRN with ranibizumab
or Bevacizumab. These results suggest that either a PRN or
a treat-and-extend regimen provides a reasonable approach
to the monthly injection protocol, although the two have not
been compared directly with each other in prospective trials
[23].
Although anti-VEGF injections have largely improve
the visual outcomes of late neovascular AMD, the risk of
visual decline and disease activity persists, and the need for
anti-VEGF treatment continues in a substantial portion of
patients. The long-time results observed after seven years in
the SEVEN-UP cohort may reflect the inexorable nature of
this chronic disease even in the face of treatment. In this
study, 98% of the study eyes were detected to have macular
atrophy whichmainly involved the fovea, as indicated by def-
inite decreased autofluorescence. Decreased visual acuity in
late neovascular AMD may be associated with macular atro-
phy and the presence of intraretinal or subretinal fluid [20].
Anti-VEGF agents with a higher affinity for VEGF mole-
cule, such as aflibercept (Eylea), offer another option [22].
Aflibercept is a promising new agent recently approved by
FDA that may lessen the treatment burden, given the encour-
aging 1-year (after three initial monthly injections) results
from the 2mg bimonthly maintenance dosing arm of the
phase 3VIEW studies compared to themonthly regimen [19].
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Preapproval clinical trials showed benefits and side effects
that were similar to those of Ranibizumab. Similar to
Ranibizumab, aflibercept binds to all VEGF isoforms (A, B,
and C) with a 10-fold higher affinity than Ranibizumab for
VEGF [24, 25].
CombinedTherapy. PDT in combination with anti-VEGF and
steroids is currently used as a second-line therapy in patients
not responding to monotherapy with anti-VEGF agents or
in whom the treatment burden of monthly injections is too
great.
Combination therapy with anti-VEGF therapy and ion-
izing radiation offers another option to reduce treatment
frequency. Radiation was never widely adopted because it did
not provide a significant, reproducible effect on visual acuity,
while difficulty delivering targeted doses led to complications
in some patients [26–29]. New options, however, such as
epimacular brachytherapy and robotic stereotactic radiother-
apy, enable safer, targeted delivery of the most appropriate
dosage, minimizing damage to surrounding structures and
improving outcomes [30–33].
Results of the phase 3 choroidal neovascularization sec-
ondary to AMD treated with beta radiation epiretinal ther-
apy trial, which compared epiretinal brachytherapy plus rani-
bizumabwith ranibizumab alone, found that the combination
was not noninferior to monotherapy with ranibizumab [34].
Ranibizumab efficacy as sole therapy and in combination
with PDT has been evaluated in several trials and 6-month
results indicate visual acuity improved by 12.8 letters with few
drug-related side effects like transient inflammation ([35],
Genentech press release: phase III study shows that Lucentis
improved vision compared to Visudyne in patients with wet
age-related macular degeneration).
1.2.3. Nonvascular AMD. Currently, there are no treatments
available for nonvascular AMD [36–38]. Transplantation of
RPE cells alone has failed to supply a sustainably functional
monolayer RPE cells, and delivery of autologous RPE cells
into the subretinal space results in insufficient cell survival
[39, 40]. Although there is evidence that the combination
of specific vitamins might slow progression of nonexudative
AMD, this involves a rather small risk group of patients.
In addition, the long-term tolerability and side effects of
high dose vitamin treatments must be carefully evaluated
[41]. Other treatment options currently evaluated in studies
are rheopheresis for extracorporeal blood filtration, which
has been undertaken in patients with early stages of AMD,
namely, drusen and small RPE atrophies [42–44]. Grid and
focal laser application and also subthreshold laser application
in patients with drusen have shown no vision recovery and an
increase in the number of neovascularizations in the treated
groups [15, 45, 46].
Surgery. Proof-of-principle for the replacement of RPE cells
has been provided by several experimental surgical proce-
dures for treating AMD [15, 47]. Macular translocation
surgery is achieved by the detachment and rotation of the
neural retina of the patient, to reposition themacula from the
diseasedmacular RPE to an area of healthy RPE cells [48–50].
However, it yields only temporary recovery of vision; the
large retinotomies associated with this procedure have high
complication rates [51] and require further surgery to repo-
sition extraocular muscles. Yet the procedure demonstrates
two important points: (1) replacing the degenerated RPE cells
does restore vision and (2) BM at the macular region is
defective and cannot support normal RPE functions since,
with time, the translocated RPE cells degenerate again. As
translocated cells survive in their original position, RPE cells
do not degenerate because of an “endogenous” defect; rather,
it appears that the substratum (BM) is not appropriate for sur-
vival. The alternative was “autologous RPE transplantation,”
which is accomplished by removing a small area of healthy
peripheral RPE and transplanting it beneath the macula to
replace the diseased RPE [52–57]. This technique carries less
risk than macular translocation, but the surgical procedure
is longer and showed postsurgery complications, such as
retinal detachment. Retinal rotation techniques may be an
alternative in a very large CNV in nonresponders to new
therapies or when it is associated with large hematomas [58].
1.3. Socioeconomic Burden. The emotional and economic
burden of AMD is often underrecognized. The prevalence
of neovascular AMD (NV-AMD), which accounts for 90%
of AMD-related severe visual impairment, increases expo-
nentially with age [59, 60]. Patients with visual impairment
such as AMD are more likely to have falls and fall-related
injuries, lose driving privileges, experience depression, and
anxiety, use special vision aids, and need assistance with day-
to-day functioning [61–63], all of which are associated with
higher resource utilization than the general population [64].
Moreover, the aging population will create a drain on our
available healthcare resources—a burden that will continue
to grow in magnitude over the next decades.
In contrast to other age-related eye diseases like cataracts
that are largely solved by current therapies, the visual prog-
nosis for most patients with AMD is poor and the late stages
of both wet and dry AMD are usually associated with severe
visual loss, which has profound effects on overall quality
of life. The shortages in executing ordinary tasks are also
extended to their psychological functioning, as evidenced by
patients with AMD reporting greater emotional distress than
visually intact peers [65].
Without treatment, the neovascular form of AMD often
leads not only to severe loss of vision but also to considerable
associated economic burden [66–68]. Despite their benefits,
frequent, indefinite injections of VEGF blocking agents
introduce a significant treatment burden for patients with
neovascular AMD. Sequential intraocular injections of anti-
VEGF agents are very expensive (1,200 euros per injection, in
addition tomonthlymedical visits) and require its application
over long periods of time (12–20 months in most cases and
subsequent retreatments). This means a high cost to the
National System of Health. Improvement obtained in
MARINA was sustained over 2 years, remarkably, but relied
on monthly injections to achieve this. This regimen is dif-
ficult for patients to maintain, particularly older patients who
may not drive, and spurs investigation of other treatment
options [69]. Some studies have been aimed to investigate
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the cost effectiveness of Ranibizumab versus Bevacizumab,
given the low cost of the last one. The average 1 year cost
of Bevacizumab was 50 times reduced versus Ranibizumab:
US$595 in the Bevacizumab versus US$23 400 in the Rani-
bizumab monthly group and US$385 in the Bevacizumab
versus US$13 800 in the Ranibizumab as-needed dosing
group. The results of the CATT study support the use of
Bevacizumab in the treatment of neovascularAMDandhigh-
light the significant economic benefit of Bevacizumab over
Ranibizumab. A recent large, multicenter, randomized pros-
pective study (ABC Trial) which demonstrated MARINA/
ANCHOR-like results lends further support for Bevacizumab
use in neovascular AMD [70]. Although bimonthly injections
certainly are less burdensome on patients thanmonthly injec-
tions, development of new pharmacologic agents and treat-
ment modalities such as regenerative medicine are ongoing
in an attempt to mitigate this burden. Interventions that
improve the morbidity caused by AMD have the potential
to greatly benefit the quality of life of individual patients, as
well as the overall economic well-being.
The economic impact of AMD on society is expected to
increase in the near future as population age and the preva-
lence of AMD increase.With newAMD therapies, healthcare
decision makers will require reliable quantitative data on
AMD-related resource utilization to evaluate alternatives, as
the ones suggested in the present review.
The mean annual direct vision-related medical cost was
reviewed by Cruess et al. and estimated to range from 2153C
per patient in the UK to 4390C per patient in Canada. The
mean direct nonvision related medical cost was estimated to
range from 597C (11% of the total cost) in the UK to 1657C
(21% of the total cost) in Canada. The annual societal costs
estimated in 2004 for bilateral NV-AMD were C1.3 billion
in Germany, C624 million in France, C511 million in the
UK, C311 million in Canada, and C268 million in Spain.
The mean annual cost per bilateral NV-AMD patient ranged
from C5300 to 12 445, of which direct vision-related medical
costs accounted for 23–63% of the total cost. These estimates
are higher than those of two previous prospective studies
[64]. Sharma and Oliver-Fernandez estimated the NV-AMD
patient annual cost to be $Can3865 (year 2004 values,
equivalent to C2715) inNorthAmerica, with 90% attributable
to direct medical costs (photodynamic therapy, 77%) and
the remainder to nonmedical costs (home support, 6%) [71].
Similarly, a study involving two French referral centres [72]
estimated a C3660 (year 2000 value) mean annual per NV-
AMD patient cost, with medical costs accounting for 51% of
the total.
There are extensive data that emphasize the need for new
treatments for AMD that will prevent vision loss and pro-
gression to blindness in order to lessen the ensuing economic
burden [73]. Overall, on the basis of current policies, age-
related public expenditure is projected to increase in average
by about 4.75 percentage points ofGDPby 2060 in theEUand
bymore than 5 percentage points in the euro area—especially
through pension, healthcare, and long-term care spending;
all of the above concepts succeed in this pathology, and it is
necessary to solve these problems in order to avoid negative
effects on general European economy. Inactive people in
active period of life generate an increase in pensions. Many
AMD sufferers are below 65 years old and they are in active
life period and they are obligated to ask for pensions. AMD is
a disease related to ageing and is associated with decreased
functional abilities and quality of life, which result in an
increase in healthcare resource utilization.
2. Cell Therapy in AMD:
Perspectives and Limitations
It has now been almost 40 years since Gouras and col-
leagues [74] showed that, using a pars plana approach, rabbit
RPE cells transplanted subretinally in rabbits survived and
phagocytized photoreceptor outer segments. Since Gouras’
work, a number of investigators have transplanted RPE cells,
iris pigment epithelial (IPE) cells, human stem cells, and
genetically modified cells in a number of animal models;
cell transplantation did prevent photoreceptor degradation
and improved vision [39, 75–82]. The positive results of cell
transplantation in animals, especially the results in the Royal
College of Surgeon (RCS) rats in which RPE degeneration is
followed by photoreceptor degeneration similar to AMD, led
to the transplantation of cell to the subretinal space of AMD
patients.
In 1997, Algvere and colleagues transplanted patches of
human fetal RPE into patient with neovascular AMD as well
as in patients with nonexudative AMD and concluded that
“it is technically feasible to transplant human RPE into the
submacular space without adversely affecting visual function
in nonexudative AMD over relatively long periods of time”
[83]. Since 1997, a number of investigators have transplanted
RPE cells, choroid-Bruch’s-RPE explants [9, 52, 53, 56, 84],
and IPE cells [85–87], and recently human embryonic stem
cells have been transplanted in one patient with geographic
atrophy [88] and a phase I/II, open-label study to determine
safety of subretinal transplantation of human embryonic stem
cell [NCT01344993] in geographic atrophy (GA) patients
is planned. Janssen Research and Development, LLC, plans
a clinical trial (NCT01226628) that will transplant human
umbilical tissue-derived cells to the subretinal space of
patients with visual impairment resulting from GA.
Since the harvesting of autologous RPE cells for trans-
plantation requires an elaborate surgical procedure, a number
of investigators have transplanted IPE cells as a substitute for
RPE cells since autologous IPE cells can be easily harvested
[89]; in vitro studies have shown that RPE and IPE share
many morphologic and functional similarities [85, 90, 91],
and transplantation of IPE cells to the subretinal space of RCS
rats prevented photoreceptor degeneration [39, 81, 92, 93].
The results of these studies have not fulfilled the promise that
cell transplantation would be the solution to the treatment
of AMD; cell transplantation has failed to show significant
improvement in vision in AMD patients.
Even though cell transplantation has failed in the past,
the successful transplantation in animal models suggests
that theoretically cell transplantation has the potential to
be a significant treatment for AMD. The failure of cell
transplantation to improve vision in AMD patients is part
of the result of the lack of knowledge of the factors that
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underlay development and progression of AMD. However,
there is enough knowledge aboutAMD to be able to construct
a theoretical framework necessary to eventually achieve
restoration of vision by cell transplantation. In general, the
approach has been to transplant autologous or homologous
cell suspensions or autologous peripheral retina choroid-BM-
RPE explants without taking into account the status of the
patient’s retina. In considering the status of the retina, two
characteristics of the disease must be taken into account,
namely, the severity and the factors underlying the disease.
For this discussion, we will assume that the severity of the
disease and loss of vision does not follow a gradient but
instead is segregated into three independent phases. Specif-
ically, initially, phase 1: RPE cells in the macular region are
intact or reversibly damaged and vision loss is the result of the
reversible loss of some function(s) by RPE cells and/or loss of
communication betweenRPE cells and photoreceptors. Later,
phase 2: RPE cells in the macular region are degenerated
or irreversibly damaged but the photoreceptors are intact
or reversibly damaged and loss of vision is the result of
nonfunctional RPE cells in the macular region. Finally, phase
3: both RPE cells in the macular region and photoreceptors
are degenerated or irreversibly damaged and loss of vision
is due to lack of both RPE cells and photoreceptors. As for
the factors underlying the disease, numerous studies have
indicated that the CNV associated with neovascular AMD
results from the lack of the proper balance between angio-
genic (VEGF) and antiangiogenic factors (pigment epithelial
derived factor, PEDF) [94, 95]. The demonstration that the
overexpression of VEGF in the retina is the driving force for
pathological neovascularization [96, 97] and overexpression
of VEGF in the retina is responsible for neovascular AMD
[98, 99] led to the development of antiangiogenic therapies
for neovascularAMD. Factors underlying geographic atrophy
are unknown; however, from studies on the viability and
rescue of photoreceptors, it appears that factors produced by
RPE cells, including basic fibroblast growth factor (bFGF),
brain-derived neurotrophic factor (BDNF), and ciliary neu-
rotrophic factor (CNTF), are responsible for normal func-
tioning of the retina and photoreceptors’ viability [100–102].
In fact, the intravitreal injection of CNTF in a feline model
of hereditary retinal degeneration leads to the long-term
survival of photoreceptors [103].
In the eye, RPE cells are the principal source of PEDF,
a neuroprotective and cytoprotective factor and a potent
inhibitor of VEGF [104, 105] that is essential in maintaining
the macula avascular [106, 107]. In neovascular AMD, there
is an overexpression of VEGF [18] and decreased levels of
antiangiogenic factors [108–112]. Here it is interesting to note
that smoking, a risk factor for neovascularAMD, is associated
with poor visual improvement after anti-VEGF treatment and
that nicotine increases theVEGF/PEDF ratio in RPE [113, 114]
indicating that VEGF is the driving force for neovascular
AMD development.
Based on the overexpression of VEGF, intravitreal admin-
istration of anti-VEGF monoclonal antibodies (Avastin or
Lucentis) has become standard therapy for neovascular AMD
with approximately 30% of patients gaining 3 or more lines
of visual acuity and stabilization in 90% of patients [37, 115,
116]. However, the short half life of the antibodies in vivo
requires repetitive, mostly monthly injections to maintain
the therapeutic effect. In addition to the difficulty and cost
of monthly treatment for elderly patients, the repetitive
intravitreal injections carry substantial risks for the patient,
for example, endophthalmitis, ocular hypertension, submac-
ular haemorrhage, and retinal detachment [117, 118]. The
difficulties associated with anti-VEGFs necessitate better and
more lasting treatments for neovascular AMD.
It was thought that transplantation of RPE cells to the
subretinal space would be a better and more permanent
treatment for AMD. However, transplantation of RPE or IPE
cell suspensions could not be an effective treatment for AMD
since normal RPE cells would not supply the increased levels
of PEDF necessary to inhibit the augmented VEGF and
possibly necessary levels of growth factors required to protect
photoreceptors from degenerations. An appropriate treat-
ment for phase 1 neovascular AMD, in which RPE cells and
photoreceptors are intact or reversibly damaged, would be the
transplantation of genetically modified, autologous pigment
epithelial (RPE or IPE) cells that would produce increased
levels of VEGF inhibitor, such as PEDF and/or endostatin.
In addition, the gene for the inhibitor of VEGF should be
integrated into the host cell genome, such that the synthesis
and secretion of the augmented PEDF would be for the life of
the patient.
Cell transplantation for the treatment of phase 2 neo-
vascular AMD, in which RPE cells are degenerated but the
photoreceptors are functional, will require genetically mod-
ified, autologous, PEDF and/or endostatin-transfected pig-
ment epithelial cells transplanted as a monolayer on a bio-
compatible substratum that supports RPE cell functions. A
biocompatible substratum is necessary since cell suspensions
transplanted to the subretinal space of AMD patients do not
attach and form a monolayer [87] because the aged BM,
especially neovascular AMD BM, is altered and does not
appear to support good attachment and survival of pigment
cells [119–123]. A number of biocompatible substrates have
been investigated and have been found to support attach-
ment, growth, and functionality of RPE cells [40, 124–126];
however, these have not been transplanted in patients. The
transplanted cell monolayer would replace the degenerated
cells and rejuvenate BM by synthesizing a new basal lamina.
Phase 3 of the disease, in which both RPE cells and pho-
toreceptors are degenerated or nonfunctional, will require the
manufacture and transplantation of a complex structure that
encompasses a biocompatible substratum upon which autol-
ogous, PEDF, and/or endostatin transfected pigment epithe-
lial cells are allowed to form a monolayer; the monolayer is
then overlaid with photoreceptor precursor cells. In animal
models of retinal degeneration, transplanted photoreceptors
integrate into the host retina and improve function [127–129].
Photoreceptor precursor can be selected from iPS cells
derived from the patient’s fibroblasts. A number of methods
have been devised to reprogram fibroblasts and induce iPS
cells [130, 131]. In the case in which both RPE cells and
photoreceptors are degenerated or nonfunctional, it may be
necessary to transplant stem cells or iPS-derived RPE cells
that may have a wider complement of factors that may be
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essential to reconstruct a BM-RPE photoreceptor complex
[58, 132–135]. iPS derived RPE cells have been shown to form
pigmented patches of typical cobble-stone cells that express
the tight junction protein ZO-1, RPE65, and bestrophin and
showed phagocytic activity by the uptake of fluorescent latex
beads [136]. Photoreceptors have been generated from iPS
cells, have been transplanted in animal models, and have
been shown to integrate into the host retina and express
photoreceptor markers [137, 138].
The essential goal of cell transplantation in neovascular
AMD, when the RPE and photoreceptors are intact or
reversibly damaged, is the effective inhibition of blood vessel
invasion of the subretinal space and restoration of RPE and
photoreceptor functions. For such purpose, the addition of
the PEDF gene to the transplanted cells should affect blood
vessel inhibition and restore RPE and photoreceptor func-
tionality. It will be critical that the PEDF gene be integrated
into the host genome so that its activity will last for the life of
the patient. For such purpose, the Sleeping Beauty (SB100X)
transposon system is ideal as the gene delivery system since
it is highly efficient, similar to retroviral vectors, but without
the associated side effects.The SB100X systemdelivers genetic
material into a target cell genome resulting in robust and
stable expression of the transgene [139–142].
For later stages of neovascular AMD and GA, it may be
necessary to introduce into the cells to be transplanted not
only the PEDF gene, but also other neuroprotective genes,
such as CNTF and IGF1 to engender a neurogenic supportive
environment. Before cell transplantation can become a rou-
tine procedure, it will be necessary to develop methodologies
to identify the stage of degeneration of RPE cells and
photoreceptors in AMD patients and transplant cell in an
appropriate genetically modified and proper architecture.
3. Tissue Engineering in AMD: Materials,
Scaffolds, and Material-Cell Interactions
Another challenge of cell therapy is the lack of cell engraft-
ment and survival in the host tissue after implantation.
Therefore, the need arises where this is assisted by artificial
supports, known as scaffolds, which are structured biocom-
patible materials that mimic the host tissue. As described
above, different cell types have been tested for treating AMD,
including RPE, IPE, retinal progenitor cells (RPC), photore-
ceptor, and stem cells [143]. Previous works highlight the
crucial role of cell adhesion onto BM, the despaired engraft-
ment derived from the deterioration of this membrane, and
they show that the best adhesion occurs on the RPE basal
lamina [144]. Therefore, tissue engineering approaches for
AMD treatment are mainly focused on the transplantation of
artificial constructs that ensure cell engraftment and activity,
overcoming the limitations of classical cell therapy and
empowering the promises of gene therapy.
3.1. Material and Fabrication. The approaches from tissue
engineering for the design and manufacturing of scaffolds
are very diverse. Decellularized matrices are the most natural
scaffolding form. The strategy consists in removing every
cell from an organ or tissue and reusing it for in vitro
recellularization and subsequent in vivo implantation. In the
particular case of retina regeneration, different natural tissues
have been tested to be used as recellularized scaffolds. In early
experiments, RPE and IPE cells have been transplanted in
vitro onto humanBM from cadaveric origin [145], Descemet’s
membranes [146], lens capsules [147], and amniotic mem-
branes (AM) [148, 149]. Furthermore, cell growth has been
modulated by performing microcontact printing on the
surface of lens capsules [150]. More recently, trabecular
meshwork mesenchymal stem cells and AM have been com-
bined, showing that differentiation towards photoreceptor-
like cells is induced [151]. Despite these advances, the access
to natural scaffolds is limited to donors; thus, artificial
scaffolds are also being developed to elude this restriction.
In soft tissues, polymeric materials are preferred for scaffold
manufacture due to their tunable capacity and similarity
with the host tissue in terms of mechanical properties. In
the case of retina, the most used polymeric material from
natural origin is collagen. Recently, in vitro and in vivo studies
have been performed where RPE cells were cultured on
ultrathin collagen membranes.They have proven to form cell
monolayers amenable in a way that permits transplantation
into subretinal space [40]. Nevertheless, the tunable capacity
of the natural polymers is limited and, in some cases, they
cannot provide the scaffold with the required properties;
therefore, synthetic polymeric materials are chosen as a
highly adjustable alternative. Some of the materials already
tested for retinal regeneration are Poly(Lactic-co-Glycolic)
Acid (PLGA), [152, 153], Poly(glycerol Sebacate) (PGS), [154],
Polycaprolactone (PCL) [155], and Poly(methyl methacry-
late) (PMMA) [156]. A detailed review of the materials
investigated for retinal regeneration has been published by
Hynes and Lavik [124].
Among the vast variety of techniques for the fabrication
of polymeric scaffolds [157], particle leaching, phase sep-
aration, and freeze-drying are the preferred ones for porous
structures. However, pointing towardsmimicry of the natural
ECM assembly, fibrous structures reproduce in a greater
extent the microscopic morphology of the native ECM.
Consequently, electrospinning has become a remarkably
advantageous technique for fibrous scaffolds. With this tech-
nique, randomly oriented polymeric fibers in the range of
1 𝜇m in diameter can be deposited; yet, up to date, no precise
deposition of the single fibers is possible and only the final
macroscopic arrangement can be customized [158, 159]. A
new technique for direct writing known as melt electrospin-
ning has recently entered the field of polymeric scaffolds,
which allows a precise control of the localization and orienta-
tion of every single electrospun fiber [160]. Nonetheless, the
dimensions are still too large for a subretinal implantation
and further scaling down of the features is necessary [161].
This technique, although still under development, offers new
alternatives for tunable structure of polymeric scaffolds in
the micrometric range. Additionally, traditional microfab-
rication techniques, which were originally employed in the
silicon industry, are lately being explored and applied in the
field of tissue engineering for the fabrication of scaffolds.
Photolithography, thin film deposition, and polymer casting
etcetera allow the production of well-defined microscopic
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topographical features on the scaffolds and enhanced cell
activity [162, 163].
3.2. Improved Biomaterial Surfaces. Control over surface
chemistry is essential to regulate the interaction between cells
and scaffolds. A traditional strategy to improve cell adhesion
on biomaterials has been the immobilization of proteins
on the surface via incubation. Thus, collagen, fibronectin,
vitronectin, laminin, and other ECM proteins were directly
bound to the surface, allowing cells to anchor onto them
[164]. An alternative to protein immobilization is peptide
immobilization, which avoids wettability and orientation
effects, and allows a tailored design of the aminoacid
sequence and precise control towards cell-scaffold interac-
tion. Peptides consist of cell recognitionmotifs that are found
in the proteins, which integrins bind to.The best knownmotif
is the RGD (arginine, glycine, and aspartic acid) sequence,
which is prevalently present in fibronectin, although other
proteins do contain varied forms of the sequence as well, such
as RGDV in vitronectin or RGDT in collagen. It has been
shown that cyclic RGDfK-type peptides with different con-
formations show enhanced integrin binding affinity and
especially selectivity [165]. One of the most recent works of
scaffolding as substitutes for BM is presented by Treharne
et al. where they develop methacrylate-based copolymers.
The copolymers are chemically modified by succinimidyl
carbonate groups; thus, the hydrophilicity altered favoring
peptide adhesion [166]. Results show enhanced peptide and
RPE cell adhesion on succinimidyl carbonate functionalized
scaffolds. Although initially surface modification was per-
formed in synthetic scaffolds, in the last years, same strategies
have started to be translated into natural origin scaffolds.
An example of that is provided by Sistiabudi and colleagues
where they modify the inner collagenous layer of Bruch’s
membrane with a collagen binding motif, where bioactive
molecules are anchored [167].
Recent strategies in biomaterials development aim at
the combination of increased hydrophilicity and minimized
unspecific protein adsorption and cell adhesion,with the abil-
ity to permit selective cell binding by the incorporation of cell
adhesion motifs. Such techniques have been developed for
flat model substrates but remain challenging for biomaterials
and three-dimensional structures. One promising one-step
technique for the generation of nonwoven textile sheets with
basal-membrane like structure and functionalization, with
large potential as artificial BM, has recently been introduced
[168].Themethod relies on the use of an amphiphilic macro-
molecular additive based on star-shaped PEO to clinically
used biodegradable polyesters during fibre generation by
electrospinning.This way, hydrophilic fibres are obtained, on
which protein adsorption and cell adhesion are minimized.
However, cell adhesion peptides can be immobilized on the
surface of these fibres, so that specific adhesion of cells onto
the fibrous sheets results. With this method, scaffolds could
be produced that influence the reaction of immune cells [169]
and thatmimic the basalmembrane in skin [170].Hence, such
strategies bear great potential for TE approaches in AMD,
where materials that mimic the BM are one key factor for
success.
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